Loading...

CN-F

CNF

CAN-FITE BIOPHARMA LTD

(CANF)

2025 6-K

Phase 2 Study Update

30 Mar '26

Financial Results Report

26 Mar '26

Patent Expansion

17 Mar '26

Shareholder Meeting Results

10 Mar '26

Warrant Exercise Agreement

5 Mar '26

Study Success

4 Mar '26

Shareholder Meeting Adjourned

3 Mar '26

Scientific Breakthrough

17 Feb '26

Patent Approval Granted

9 Feb '26

Liver Transplant Success

5 Feb '26

General Meeting Notice

27 Jan '26

Patient Enrollment Completed

20 Jan '26

Board Resignation

16 Jan '26

Patent Granted

29 Dec '25

Share Split Announcement

23 Dec '25

Company Update

16 Dec '25

Warrant Price Reduction

21 Nov '25

Patent Allowance News

20 Nov '25

Latest Patient Update

18 Nov '25

Shareholder Meeting Results

10 Nov '25

Shareholder Meeting Delay

3 Nov '25

Shareholder Meeting Notice

3 Oct '25

Treatment Success

15 Sep '25

Financial Results Update

28 Aug '25

Enrollment Milestone

30 Jul '25

Capital Raising Initiative

29 Jul '25

Public Offering Announcement

28 Jul '25

Breakthrough Study

28 Jul '25

Shareholders Meeting

30 Jun '25

Annual Meeting Update

23 Jun '25

Study Announcement

16 Jun '25

Annual Meeting Notice

16 May '25

Funding Announcement

5 May '25

FDA Approval News

17 Apr '25

Securities Offering

15 Apr '25

Funding Announcement

14 Apr '25

Future Revenue Projection

14 Apr '25

Financial Update

14 Apr '25

Psoriasis Study Initiated

24 Mar '25

Clinical Trial Update

20 Mar '25

Phase II Study

19 Mar '25

FDA Approval Announcement

18 Mar '25

New Publication Release

3 Mar '25

Liver Treatment Update

18 Feb '25

Conference Announcement

5 Feb '25

Patent Granted

27 Jan '25

ASCO Recognition

30 Dec '24

Survival Success

4 Dec '24

Clinical Trial Milestone

12 Nov '24

Patent Allowance

4 Nov '24

Positive Study Results

18 Oct '24

FDA Approval Granted

9 Oct '24

Projected Income Announcement

24 Sep '24

Regulatory Approval Received

16 Sep '24

New Offering Agreement

30 Aug '24

Financial Results Update

29 Aug '24

Warrant Exercise Agreement

12 Aug '24

Warrants Exercise

9 Aug '24

Patent Update Report

29 Jul '24

FDA Orphan Drug Application

11 Jul '24

Shareholder Meeting Results

3 Jul '24

Treatment Improvement

1 Jul '24

Positive Study Results

28 Jun '24

Annual Meeting Delay

26 Jun '24

Breakthrough Findings

24 Jun '24

IRB Approval Received

10 Jun '24

Proxy Amendment Notice

7 Jun '24

Liver Cancer Update

5 Jun '24

Therapeutic Effects

29 May '24

Annual Meeting Notice

22 May '24

Conference Participation

13 May '24

FDA Clearance Granted

9 May '24

Patent Allowance Notification

6 May '24

Scientific Publication

25 Apr '24

Drug Candidate Update

15 Apr '24

FDA Application Submitted

3 Apr '24

Financial Results Update

28 Mar '24

Partnering Announcement

11 Mar '24

Patent Allowance Granted

28 Feb '24

Out-Licensing Expansion

30 Jan '24

Positive Psoriasis Data

29 Jan '24

External Links:

SEC

On January 27, 2025, Can-Fite BioPharma Ltd. announced that the US Patent Office granted a patent for Namodenoson as an anti-obesity drug. This filing is significant for the company's growth and innovation strategies.

AI Assistant

CAN-FITE BIOPHARMA LTD

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.